Ziad Skaff, MD
Hematology & Oncology · Charleston, SCNPI 1770601734
Payments from drug & device makers
Across 111 payments — averaging $22.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$297
- Novartis$216
- Daiichi Sankyo Inc.$192
- Merz North America, Inc.$176
- Merck$176
- Sanofi$175
- plus $1K from 25 others
What the payments were for
- Food & beverage$2,501100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 12 | $297 |
| Novartis | 10 | $216 |
| Daiichi Sankyo Inc. | 7 | $192 |
| Merz North America, Inc. | 2 | $176 |
| Merck | 9 | $176 |
| Sanofi | 7 | $175 |
| Gilead(2 entities) | 5 | $125 |
| Bristol Myers Squibb | 6 | $123 |
| Amgen | 6 | $114 |
| AstraZeneca(2 entities) | 5 | $105 |
| Johnson & Johnson | 4 | $82 |
| Eisai Inc. | 4 | $82 |
| EMD Serono, Inc. | 4 | $71 |
| Pfizer | 4 | $63 |
| GSK | 3 | $63 |
| Rigel Pharmaceuticals, Inc. | 3 | $58 |
| Ipsen Biopharmaceuticals, Inc | 2 | $42 |
| Lilly USA, LLC | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Genentech USA, Inc. | 2 | $33 |
| Pharmaessentia USA Corporation | 1 | $24 |
| Incyte Corporation | 1 | $24 |
| Blue Earth Diagnostics | 1 | $23 |
| Coherus Oncology, Inc. | 1 | $21 |
| Seagen Inc. | 1 | $21 |
| Servier Pharmaceuticals LLC | 1 | $20 |
| Stemline Therapeutics Inc. | 1 | $19 |
| Pharmacosmos Therapeutics Inc. | 1 | $16 |
| Dova Pharmaceuticals | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$116
How this compares
$2,501 in reported general payments places this provider in the 30th percentile of 166 hematology & oncology providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 101 | $1,413,379 |
| ImbruvicaIbrutinib | 21 | $360,475 |
| CabometyxCabozantinib S-Malate | 14 | $337,692 |
| PomalystPomalidomide | 16 | $335,961 |
| XtandiEnzalutamide | 16 | $229,258 |
| VerzenioAbemaciclib | 14 | $173,254 |
| EliquisApixaban | 42 | $30,265 |
| OzempicSemaglutide | 25 | $25,730 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $18,518 |
| BrilintaTicagrelor | 24 | $12,392 |
| XareltoRivaroxaban | 17 | $11,069 |
| JanuviaSitagliptin Phosphate | 11 | $8,558 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 12 | $7,204 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 137 | $4,157 |
| Oxycodone Hcl | 179 | $3,360 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $123 | $1,413,379101 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $297 | $335,96116 claims |
| Lilly USA, LLCVerzenio | $40 | $173,25414 claims |
| PfizerEliquis | $63 | $30,26542 claims |
| AstraZenecaBrilinta, Breztri Aerosphere | $105 | $19,59636 claims |
| GSKTrelegy Ellipta | $63 | $18,51824 claims |
| Johnson & JohnsonXarelto | $82 | $11,06917 claims |
| MerckJanuvia | $176 | $8,55811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 166 hematology & oncology providers in South Carolina.
Other hematology & oncology in Charleston
- Robert StuartCharleston$2.9M
- Brian LingerfeltCharleston$1.1M
- James OrcuttCharleston$1.1M
- George GeilsCharleston$930K
- John WrangleCharleston$919K
- David EllisonCharleston$767K
- George KeoghCharleston$745K
- Russell JenkinsCharleston$627K
- Irl GreenwellCharleston$376K
- Ming LimCharleston$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.